Evidence map›Paper›PMID 25063076›Full record

ArticleNeuromolecular medicine2014

Inhibitors of histone deacetylases enhance neurotoxicity of DNA damage.

A Vashishta, M Hetman

Open access · greenAbstract readComparative Study
In one paragraph

Article in Neuromolecular medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

A VashishtaKentucky Spinal Cord Injury Research Center, Department of Neurological Surgery, University of Louisville, 511 S. Floyd St., MDR616, Louisville, KY, 40292, USA.
M Hetman
University of Louisville · US

Funding

Mechanisms of plasticity and repair after SCIP30GM103507 · NIGMS · UNIVERSITY OF LOUISVILLE · PI WHITTEMORE, SCOTT R · 2012 to 2015
$4.2M
ER stress and oligodendrocyte survival after spinal cord injuryR01NS073584 · NINDS · UNIVERSITY OF LOUISVILLE · PI HETMAN, MICHAL, WHITTEMORE, SCOTT R · 2011 to 2015
$2.1M
NIGMS NIH HHS 8P30GM103507NIGMS NIH HHS P30 GM103507NINDS NIH HHS NS073584NINDS NIH HHS R01 NS073584
6 · The paper itself

Abstract

The nonselective inhibitors of class I/II histone deacetylases (HDACs) including trichostatin A and the clinically used suberoylanilide hydroxamic acid (SAHA, vorinostat) are neuroprotective in several models of neuronal injury. Here, we report that in cultured cortical neurons from newborn rats and in the cerebral cortex of whole neonate rats, these HDAC inhibitors exacerbated cytotoxicity of the DNA double-strand break (DSB)-inducing anticancer drug etoposide by enhancing apoptosis. Similar neurotoxic interactions were also observed in neurons that were treated with other DNA damaging drugs including cisplatin and camptothecin. In addition, in rat neonates, SAHA increased cortical neuron apoptosis that was induced by a single injection of the NMDA receptor antagonist dizocilpine (MK801). In etoposide-treated neurons, the nonselective HDAC inhibition resulted in more DSBs. It also potentiated etoposide-induced accumulation and phosphorylation of the pro-apoptotic transcription factor p53. Moreover, nonselective HDAC inhibition exacerbated neuronal apoptosis that was induced by the overexpressed p53. Importantly, such effects cannot be fully explained by inhibition of HDAC1, which is known to play a role in DSB repair and regulation of p53. The specific HDAC1 inhibitor MS275 only moderately enhanced etoposide-induced neuronal death. Although in etoposide-treated neurons MS275 increased DSBs, it did not affect activation of p53. Our findings suggest that besides HDAC1, there are other class I/II HDACs that participate in neuronal DNA damage response attenuating neurotoxic consequences of genotoxic insults to the developing brain.

Indexed as

AnimalsAnimals, NewbornAntineoplastic AgentsApoptosisBenzamidesCamptothecinCells, CulturedCerebral CortexCisplatinDizocilpine MaleateDNA Breaks, Double-StrandedEtoposideGenes, p53Histone Deacetylase 1Histone Deacetylase InhibitorsHydroxamic AcidsAntineoplastic AgentsBenzamidesCamptothecinCisplatinDizocilpine MaleateentinostatEtoposideHdac1 protein, ratHistone Deacetylase 1Histone Deacetylase InhibitorsHydroxamic AcidsPyridinesTumor Suppressor Protein p53Vorinostat

Identifiers

PMID25063076
PMCPMC4229421
OpenAlexW2084660043

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.